Ignite Creation Date:
2024-05-06 @ 7:01 PM
Last Modification Date:
2024-10-26 @ 2:59 PM
Study NCT ID:
NCT05869227
Status:
RECRUITING
Last Update Posted:
2024-06-03
First Post:
2023-05-11
Brief Title:
Maintenance Therapy With Toripalimab Combined With CapecitabinePlacebo for Recurrent and Metastatic Nasopharyngeal Carcinoma
Sponsor:
XIANG YANQUN
Organization:
Sun Yat-sen University
Study Overview
Official Title:
The Efficacy and Safety of Maintenance Therapy With Toripalimab Combined With CapecitabinePlacebo for Recurrent and Metastatic Nasopharyngeal CarcinomaRandomized Double-blind Placebo-controlled Multicenter Phase III Clinical Study
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study is to investigate the efficacy and safety of the capecitabine combined with toripalimab maintenance regimen in improving the first-line treatment of recurrent and metastatic nasopharyngeal carcinoma after receiving remission through chemotherapy combined with anti PD-1 monoclonal antibody standard regimen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None